Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

550 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relapsed refractory multiple myeloma: a comprehensive overview.
Bazarbachi AH, Al Hamed R, Malard F, Harousseau JL, Mohty M. Bazarbachi AH, et al. Among authors: harousseau jl. Leukemia. 2019 Oct;33(10):2343-2357. doi: 10.1038/s41375-019-0561-2. Epub 2019 Aug 27. Leukemia. 2019. PMID: 31455853 Review.
Daratumumab in transplant regimens for myeloma?
Harousseau JL, Mohty M. Harousseau JL, et al. Blood. 2020 Aug 20;136(8):917-918. doi: 10.1182/blood.2020006298. Blood. 2020. PMID: 32818244 Free article. No abstract available.
Up-front ixazomib in older patients with myeloma.
Harousseau JL, Mohty M. Harousseau JL, et al. Blood. 2021 Jul 1;137(26):3584-3586. doi: 10.1182/blood.2021011262. Blood. 2021. PMID: 34196682 Free article. No abstract available.
Requirements for operational cure in multiple myeloma.
Mohty M, Avet-Loiseau H, Harousseau JL. Mohty M, et al. Among authors: harousseau jl. Blood. 2021 Oct 21;138(16):1406-1411. doi: 10.1182/blood.2021012854. Blood. 2021. PMID: 34324647 Free article.
Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma.
Clavert A, Le Gouill S, Brissot E, Dubruille V, Mahe B, Gastinne T, Blin N, Chevallier P, Guillaume T, Delaunay J, Ayari S, Saulquin B, Moreau A, Moreau P, Harousseau JL, Milpied N, Mohty M. Clavert A, et al. Among authors: harousseau jl. Leuk Lymphoma. 2010 Aug;51(8):1502-8. doi: 10.3109/10428194.2010.497981. Leuk Lymphoma. 2010. PMID: 20583964 Clinical Trial.
Comprehensive Review of AL amyloidosis: some practical recommendations.
Al Hamed R, Bazarbachi AH, Bazarbachi A, Malard F, Harousseau JL, Mohty M. Al Hamed R, et al. Among authors: harousseau jl. Blood Cancer J. 2021 May 18;11(5):97. doi: 10.1038/s41408-021-00486-4. Blood Cancer J. 2021. PMID: 34006856 Free PMC article. Review.
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Garderet L, Iacobelli S, Moreau P, Dib M, Lafon I, Niederwieser D, Masszi T, Fontan J, Michallet M, Gratwohl A, Milone G, Doyen C, Pegourie B, Hajek R, Casassus P, Kolb B, Chaleteix C, Hertenstein B, Onida F, Ludwig H, Ketterer N, Koenecke C, van Os M, Mohty M, Cakana A, Gorin NC, de Witte T, Harousseau JL, Morris C, Gahrton G. Garderet L, et al. Among authors: harousseau jl. J Clin Oncol. 2012 Jul 10;30(20):2475-82. doi: 10.1200/JCO.2011.37.4918. Epub 2012 May 14. J Clin Oncol. 2012. PMID: 22585692 Clinical Trial.
550 results